# Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
Canonical URL: https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-citi-2026-virtual-o-fa58ccae
Ticker: CGEM
Company: Cullinan Therapeutics, Inc.
Source: Cullinan Therapeutics, Inc.
Published: 2026-02-18 12:00 EST
## Summary

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company...

## Article Body
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events .

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/ , and follow Cullinan on LinkedIn and X .

Contacts:

Investors Nick Smith +1 401.241.3516 nsmith@cullinantx.com

Media Rose Weldon +1 215.801.7644 rweldon@cullinantx.com
## Recent Company News
- 2026-07-28 11:00 EST — [Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-announces-positive-end-of-phase-1-meeting-with-fda-for-cln-68006175) — Source: Cullinan Therapeutics, Inc.
- 2026-06-10 11:30 EST — [Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-of-t-cell-en-1824446e) — Source: Cullinan Therapeutics, Inc.
- 2026-06-06 09:15 EST — [Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-ce-5c413068) — Source: Cullinan Therapeutics, Inc.
- 2026-05-26 11:00 EST — [Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-host-immunology-day-to-showcase-promising-initial-clini-cc2e30f1) — Source: Cullinan Therapeutics, Inc.
- 2026-05-19 11:00 EST — [Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-cln-049-a-novel-f-c84381bb) — Source: Cullinan Therapeutics, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)